0000000001298704

AUTHOR

Angelo Guido Corsico

showing 7 related works from this author

Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe…

2021

Background: ANDHI was done to assess the efficacy of benralizumab, including onset of effect and impact on health-related quality of life (HRQOL), exacerbation rate, lung function, and nasal polyposis symptoms. Methods: This phase 3b, randomised, double-blind, parallel-group, placebo-controlled ANDHI study was completed in adults (aged 18–75 years) with severe eosinophilic asthma with at least 2 exacerbations in the previous year, despite high-dose inhaled corticosteroid plus additional controllers, screening blood eosinophil counts of at least 150 cells per μL, and an Asthma Control Questionnaire 6 (ACQ-6) score of 1·5 or more. Patients who met eligibility criteria were randomly assigned (…

Pulmonary and Respiratory MedicineSpirometryAdultMalemedicine.medical_specialtyExacerbation[SDV]Life Sciences [q-bio]PopulationSettore MED/10 - Malattie Dell'Apparato RespiratorioPlaceboAntibodies Monoclonal Humanized03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDouble-Blind MethodInternal medicinemedicineHumans030212 general & internal medicineAnti-Asthmatic AgentsPatient Reported Outcome MeasureseducationSinusitisAsthmaeducation.field_of_studymedicine.diagnostic_testbusiness.industryMiddle Agedmedicine.diseaseBenralizumabAsthma3. Good healthEosinophils030228 respiratory systemchemistryAsthma Control QuestionnaireSpirometryDisease ProgressionQuality of LifeFemalebusiness
researchProduct

Satisfaction with chronic obstructive pulmonary disease treatment: results from a multicenter, observational study

2019

Background: Understanding the level of patients’ satisfaction with treatment and its determinants have the potential to impact therapeutic management and clinical outcome in chronic conditions such as chronic obstructive pulmonary disease (COPD). Methods: A national, multicenter, longitudinal, observational study of COPD from 20 Italian pulmonary centers to explore patients’ satisfaction to treatment [assessed by the Treatment Satisfaction Questionnaire, 9 items (TSQM-9)] and association with clinical parameters [including dyspnea score, COPD Assessment Test (CAT) score, exacerbation rate], adherence to treatment [Morisky Medication-Taking Adherence Scale (MMAS-4)], illness perception [eval…

Pulmonary and Respiratory MedicineMaleChronic Obstructivemedicine.medical_specialtyCOPD; adherence; treatment satisfactionPulmonary diseaseSocio-culturaleTreatment resultstreatment satisfactionSettore MED/10 - Malattie Dell'Apparato RespiratorioOutcome (game theory)Medication AdherencePulmonary Disease03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineSurveys and QuestionnairesAdministration InhalationSettore MED/10MedicineHumansCOPDPharmacology (medical)030212 general & internal medicineadherenceIntensive care medicineOriginal ResearchAgedlcsh:RC705-779adherence COPD treatment satisfactionbusiness.industrylcsh:Diseases of the respiratory systemMiddle AgedDyspneaInhalation030228 respiratory systemItalyPatient SatisfactionAdministrationObservational studyFemalebusinessFollow-Up Studies
researchProduct

Nutritional parameters associated with prognosis in non-critically ill hospitalized covid-19 patients: the nutri-covid19 study

2021

Background & aims: To investigate the association between the parameters used in nutritional screening assessment (body mass index [BMI], unintentional weight loss [WL] and reduced food intake) and clinical outcomes in non-critically ill, hospitalized coronavirus disease 2019 (COVID-19) patients. Methods: This was a prospective multicenter real-life study carried out during the first pandemic wave in 11 Italian Hospitals. In total, 1391 patients were included. The primary end-point was a composite of in-hospital mortality or admission to ICU, whichever came first. The key secondary end-point was in-hospital mortality. Results: Multivariable models were based on 1183 patients with comple…

Poor prognosisFood intake2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Endocrinology Diabetes and MetabolismSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Nutritional riskNutritional StatusESPEN Best AbstractsCritical Care and Intensive Care MedicineWeight lossFood intakeInternal medicineHumansMedicineProspective StudiesObesityObesity.MortalityIntensive care medicineNutrition and DieteticsCoronavirus disease 2019business.industryCritically illMalnutritionCOVID-19Prognosismedicine.diseaseObesityHospitalizationMalnutritionNutrition Assessmentmedicine.symptombusinessBody mass indexClinical Nutrition Espen
researchProduct

Comparison between Suspected and Confirmed COVID-19 Respiratory Patients: What Is beyond the PCR Test

2022

COVID-19 modified the healthcare system. Nasal-pharyngeal swab (NPS), with real-time reverse transcriptase-polymerase (PCR), is the gold standard for the diagnosis; however, there are difficulties related to the procedure that may postpone it. The study aims to evaluate whether other elements than the PCR-NPS are reliable and confirm the diagnosis of COVID-19. This is a cross-sectional study on data from the Lung Unit of Pavia (confirmed) and at the Emergency Unit of Palermo (suspected). COVID-19 was confirmed by positive NPS, suspected tested negative. We compared clinical, laboratory and radiological variables and performed Logistic regression to estimate which variables increased the ris…

COVID-19 diagnosiCOVID-19; PCR test; COVID-19 diagnosisCOVID-19General MedicinePCR testSettore MED/10 - Malattie Dell'Apparato Respiratorio
researchProduct

Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life

2021

Abstract Background and aims Severe asthma is burdened by frequent exacerbations and use of oral corticosteroids (OCS) which worsen patients’ health and increase healthcare spending. Aim of this study was to assess the clinical and economic effect of adding mepolizumab (MEP) for the treatment of these patients. Methods Patients >18 years old, referred to 8 asthma clinics, starting MEP between May 2017 and December 2018, were enrolled and followed-up for 12 months. Information in the 12 months before mepolizumab were collected retrospectively. The evaluation parameters included: OCS use, number of exacerbations/hospitalizations, concomitant therapies, comorbidity, and annual number of workin…

OR Odds RatioPediatricsSevere asthmaExacerbationAnti IL-5; Comorbidities; Mepolizumab; OCS; Pharmacoeconomics; Severe asthmagastroesophageal reflux diseaseSettore MED/10 - MALATTIE DELL'APPARATO RESPIRATORIOICS inhaled corticosteroidRate ratioOCS Oral Corticosteroidslaw.inventionComorbiditiesLAMA long acting muscarinic antagonist0302 clinical medicineRandomized controlled trialfractional nitric oxideInterquartile rangelawlong acting beta 2 agonistOdds RatioImmunology and AllergyRR Rate Ratio030223 otorhinolaryngologyPharmacoeconomicLOS Length of stayLOSIQRLAMAMEP MepolizumabORCISD Standard DeviationMEPPharmacoeconomicsACT Asthma Control TestComorbiditieCI Confidence Intervalsmedicine.druglcsh:Immunologic diseases. AllergyPulmonary and Respiratory Medicinemedicine.medical_specialtyinterquartile rangelong acting muscarinic antagonistImmunologyLABALABA long acting beta 2 agonistComorbidities Mepolizumab OCS Pharmacoeconomics Severe asthma Anti IL-5RRArticleRate Ratiochronic obstructive pulmonary disease03 medical and health sciencesPharmacoeconomicsOCS Oral CorticosteroidAsthma Control TestConfidence IntervalsFeNO fractional nitric oxideRCTs Randomized Controlled TrialmedicineCOPDGERD gastroesophageal reflux diseaseFeNOIQR interquartile rangeMepolizumabSDAsthmaRCTsOral Corticosteroidsbusiness.industryGERDmedicine.diseaseICS inhaled corticosteroidsACTComorbidityRandomized Controlled TrialsCI Confidence IntervalRCTs Randomized Controlled TrialsOCSCOPD chronic obstructive pulmonary disease030228 respiratory systemICSStandard DeviationLength of stayAnti IL-5inhaled corticosteroidslcsh:RC581-607businessMepolizumab
researchProduct

Chronic obstructive lung disease “expert system”: Validation of a predictive tool for assisting diagnosis

2018

Purpose: The purposes of this study were development and validation of an expert system (ES) aimed at supporting the diagnosis of chronic obstructive lung disease (COLD). Methods: A questionnaire and a WebFlex code were developed and validated in silico. An expert panel pilot validation on 60 cases and a clinical validation on 241 cases were performed. Results: The developed questionnaire and code validated in silico resulted in a suitable tool to support the medical diagnosis. The clinical validation of the ES was performed in an academic setting that included six different reference centers for respiratory diseases. The results of the ES expressed as a score associated with the risk of su…

Pulmonary and Respiratory MedicineChronic ObstructivePilot ProjectsExpert SystemsSettore MED/10 - Malattie Dell'Apparato RespiratorioPulmonary DiseasePulmonary Disease Chronic ObstructiveSoftware DesignSurveys and QuestionnairesChronic obstructive lung diseaseDiagnosisSurveys and QuestionnaireHumansAge FactorPilot ProjectExpert SystemChronic obstructive lung diseasesAgedHealth PolicyEnvironmental and Occupational HealthPublic Health Environmental and Occupational HealthMethodologyAge FactorsChronic obstructive lung diseases Diagnosis Expert systems Pulmonary and Respiratory Medicine Health Policy Public Health Environmental and Occupational HealthMiddle AgedAsthmaCoughSpirometrySample SizeChronic DiseasePublic HealthChronic obstructive lung diseases; Diagnosis; Expert systems; Age Factors; Aged; Asthma; Chronic Disease; Cough; Humans; Middle Aged; Pilot Projects; Pulmonary Disease Chronic Obstructive; Sample Size; Spirometry; Expert Systems; Software Design; Surveys and QuestionnairesDiagnosiHuman
researchProduct

Supplementary_Material – Supplemental material for Cost-description and multiple imputation of missing values: the SATisfaction and adherence to COPD…

2018

Supplemental material, Supplementary_Material for Cost-description and multiple imputation of missing values: the SATisfaction and adherence to COPD treatment (SAT) study by Carlo Lazzaro, Fabiano Di Marco, Nicola Scichilone, Fulvio Braido, Marco Contoli, Paola Rogliani, Pierachille Santus, Valentina Acciai, Carla Scognamillo, Irene Olivi and Angelo Guido Corsico in Global & Regional Health Technology Assessment

111708 Health and Community ServicesFOS: Health sciences
researchProduct